| 1 | 
                
                    CTLA4
                
             💬
 | [4]  Cell adhesion molecules Cell adhesion molecules, T cell receptor signaling pathway, Autoimmune thyroid disease, Rheumatoid arthritis | Ipilimumab 
                
                    Ipilimumab
                
             💬
 | 
                
                    Ipilimumab
                
             | [1]  159 159 💬
 | 
| 2 | 
                
                    CTLA4
                
             💬
 | [4]  Cell adhesion molecules Cell adhesion molecules, T cell receptor signaling pathway, Autoimmune thyroid disease, Rheumatoid arthritis | Tremelimumab 
                
                    Tremelimumab
                
             💬
 | 
                
                    Tremelimumab
                
             | [1]  96 96 💬
 | 
| 3 | 
                
                    IFNA1
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Rontalizumab 
                
                    Rontalizumab
                
             💬
 | 
                
                    Rontalizumab
                
             | [1]  49 49 💬
 | 
| 4 | 
                
                    IFNA1
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Sifalimumab 
                
                    Sifalimumab
                
             💬
 | 
                
                    Sifalimumab
                
             | [1]  49 49 💬
 | 
| 5 | 
                
                    IFNA2
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Rontalizumab 
                
                    Rontalizumab
                
             💬
 | 
                
                    Rontalizumab
                
             | [1]  49 49 💬
 | 
| 6 | 
                
                    IFNA2
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Sifalimumab 
                
                    Sifalimumab
                
             💬
 | 
                
                    Sifalimumab
                
             | [1]  49 49 💬
 | 
| 7 | 
                
                    IFNA4
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Rontalizumab 
                
                    Rontalizumab
                
             💬
 | 
                
                    Rontalizumab
                
             | [1]  49 49 💬
 | 
| 8 | 
                
                    IFNA4
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Sifalimumab 
                
                    Sifalimumab
                
             💬
 | 
                
                    Sifalimumab
                
             | [1]  49 49 💬
 | 
| 9 | 
                
                    IFNA5
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Rontalizumab 
                
                    Rontalizumab
                
             💬
 | 
                
                    Rontalizumab
                
             | [1]  49 49 💬
 | 
| 10 | 
                
                    IFNA5
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Sifalimumab 
                
                    Sifalimumab
                
             💬
 | 
                
                    Sifalimumab
                
             | [1]  49 49 💬
 | 
| 11 | 
                
                    IFNA6
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Rontalizumab 
                
                    Rontalizumab
                
             💬
 | 
                
                    Rontalizumab
                
             | [1]  49 49 💬
 | 
| 12 | 
                
                    IFNA6
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Sifalimumab 
                
                    Sifalimumab
                
             💬
 | 
                
                    Sifalimumab
                
             | [1]  49 49 💬
 | 
| 13 | 
                
                    IFNA7
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Rontalizumab 
                
                    Rontalizumab
                
             💬
 | 
                
                    Rontalizumab
                
             | [1]  49 49 💬
 | 
| 14 | 
                
                    IFNA7
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Sifalimumab 
                
                    Sifalimumab
                
             💬
 | 
                
                    Sifalimumab
                
             | [1]  49 49 💬
 | 
| 15 | 
                
                    IFNA8
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Rontalizumab 
                
                    Rontalizumab
                
             💬
 | 
                
                    Rontalizumab
                
             | [1]  49 49 💬
 | 
| 16 | 
                
                    IFNA8
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Sifalimumab 
                
                    Sifalimumab
                
             💬
 | 
                
                    Sifalimumab
                
             | [1]  49 49 💬
 | 
| 17 | 
                
                    IFNA10
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Rontalizumab 
                
                    Rontalizumab
                
             💬
 | 
                
                    Rontalizumab
                
             | [1]  49 49 💬
 | 
| 18 | 
                
                    IFNA10
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Sifalimumab 
                
                    Sifalimumab
                
             💬
 | 
                
                    Sifalimumab
                
             | [1]  49 49 💬
 | 
| 19 | 
                
                    IFNA13
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Rontalizumab 
                
                    Rontalizumab
                
             💬
 | 
                
                    Rontalizumab
                
             | [1]  49 49 💬
 | 
| 20 | 
                
                    IFNA13
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Sifalimumab 
                
                    Sifalimumab
                
             💬
 | 
                
                    Sifalimumab
                
             | [1]  49 49 💬
 | 
| 21 | 
                
                    IFNA14
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Rontalizumab 
                
                    Rontalizumab
                
             💬
 | 
                
                    Rontalizumab
                
             | [1]  49 49 💬
 | 
| 22 | 
                
                    IFNA14
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Sifalimumab 
                
                    Sifalimumab
                
             💬
 | 
                
                    Sifalimumab
                
             | [1]  49 49 💬
 | 
| 23 | 
                
                    IFNA16
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Rontalizumab 
                
                    Rontalizumab
                
             💬
 | 
                
                    Rontalizumab
                
             | [1]  49 49 💬
 | 
| 24 | 
                
                    IFNA16
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Sifalimumab 
                
                    Sifalimumab
                
             💬
 | 
                
                    Sifalimumab
                
             | [1]  49 49 💬
 | 
| 25 | 
                
                    IFNA17
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Rontalizumab 
                
                    Rontalizumab
                
             💬
 | 
                
                    Rontalizumab
                
             | [1]  49 49 💬
 | 
| 26 | 
                
                    IFNA17
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Sifalimumab 
                
                    Sifalimumab
                
             💬
 | 
                
                    Sifalimumab
                
             | [1]  49 49 💬
 | 
| 27 | 
                
                    IFNA21
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Rontalizumab 
                
                    Rontalizumab
                
             💬
 | 
                
                    Rontalizumab
                
             | [1]  49 49 💬
 | 
| 28 | 
                
                    IFNA21
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Sifalimumab 
                
                    Sifalimumab
                
             💬
 | 
                
                    Sifalimumab
                
             | [1]  49 49 💬
 | 
| 29 | 
                
                    IL4
                
             💬
 | [16]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Intestinal immune network for IgA production, Leishmaniasis, Pathways in cancer, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Allograft rejection | Binetrakin 
                
                    Binetrakin
                
             💬
 | 
                
                    Binetrakin
                
             | [1]  46 46 💬
 | 
| 30 | 
                
                    IL5
                
             💬
 | [13]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th1 and Th2 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Intestinal immune network for IgA production, Pathways in cancer, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Allograft rejection | Mepolizumab 
                
                    Mepolizumab
                
             💬
 | 
                
                    Mepolizumab
                
             | [4]  44 44, 45, 98, 162 💬
 | 
| 31 | 
                
                    IL5
                
             💬
 | [13]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th1 and Th2 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Intestinal immune network for IgA production, Pathways in cancer, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Allograft rejection | Reslizumab 
                
                    Reslizumab
                
             💬
 | 
                
                    Reslizumab
                
             | [2]  44 44, 98 💬
 | 
| 32 | 
                
                    IL10
                
             💬
 | [22]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, FoxO signaling pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, T cell receptor signaling pathway, Intestinal immune network for IgA production, Pertussis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Staphylococcus aureus infection, Tuberculosis, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Systemic lupus erythematosus, Allograft rejection | Pirfenidone 
                
                    Pirfenidone
                
             💬
 | 
                
                    Pirfenidone
                
             | [11]  13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
 | 
| 33 | 
                
                    TPO
                
             💬
 | [4]  Tyrosine metabolism Tyrosine metabolism, Metabolic pathways, Thyroid hormone synthesis, Autoimmune thyroid disease | Methimazole 
                
                    Methimazole
                
             💬
 | 
                
                    Methimazole
                
             | [1]  50 50 💬
 | 
| 34 | 
                
                    CD80
                
             💬
 | [11]  Virion - Adenovirus Virion - Adenovirus, Cell adhesion molecules, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Type I diabetes mellitus, Autoimmune thyroid disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis | Abatacept 
                
                    Abatacept
                
             💬
 | 
                
                    Abatacept
                
             | [26]  11 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
 | 
| 35 | 
                
                    CD80
                
             💬
 | [11]  Virion - Adenovirus Virion - Adenovirus, Cell adhesion molecules, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Type I diabetes mellitus, Autoimmune thyroid disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis | Belatacept 
                
                    Belatacept
                
             💬
 | 
                
                    Belatacept
                
             | [1]  46 46 💬
 | 
| 36 | 
                
                    CD86
                
             💬
 | [13]  Virion - Adenovirus Virion - Adenovirus, Cell adhesion molecules, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Type I diabetes mellitus, Kaposi sarcoma-associated herpesvirus infection, Transcriptional misregulation in cancer, Autoimmune thyroid disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis | Abatacept 
                
                    Abatacept
                
             💬
 | 
                
                    Abatacept
                
             | [26]  11 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
 | 
| 37 | 
                
                    CD86
                
             💬
 | [13]  Virion - Adenovirus Virion - Adenovirus, Cell adhesion molecules, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Type I diabetes mellitus, Kaposi sarcoma-associated herpesvirus infection, Transcriptional misregulation in cancer, Autoimmune thyroid disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis | Belatacept 
                
                    Belatacept
                
             💬
 | 
                
                    Belatacept
                
             | [1]  46 46 💬
 | 
| 38 | 
                
                    CD40
                
             💬
 | [17]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Cell adhesion molecules, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Malaria, Toxoplasmosis, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Transcriptional misregulation in cancer, Asthma, Autoimmune thyroid disease, Systemic lupus erythematosus, Allograft rejection, Primary immunodeficiency, Viral myocarditis, Lipid and atherosclerosis | Bleselumab 
                
                    Bleselumab
                
             💬
 | 
                
                    Bleselumab
                
             | [1]  222 222 💬
 | 
| 39 | 
                
                    CD40
                
             💬
 | [17]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Cell adhesion molecules, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Malaria, Toxoplasmosis, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Transcriptional misregulation in cancer, Asthma, Autoimmune thyroid disease, Systemic lupus erythematosus, Allograft rejection, Primary immunodeficiency, Viral myocarditis, Lipid and atherosclerosis | Ravagalimab 
                
                    Ravagalimab
                
             💬
 | 
                
                    Ravagalimab
                
             | [2]  53 53, 97 💬
 | 
| 40 | 
                
                    CD40
                
             💬
 | [17]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Cell adhesion molecules, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Malaria, Toxoplasmosis, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Transcriptional misregulation in cancer, Asthma, Autoimmune thyroid disease, Systemic lupus erythematosus, Allograft rejection, Primary immunodeficiency, Viral myocarditis, Lipid and atherosclerosis | Iscalimab 
                
                    Iscalimab
                
             💬
 | 
                
                    Iscalimab
                
             | [2]  49 49, 53 💬
 | 
| 41 | 
                
                    CD40LG
                
             💬
 | [14]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Cell adhesion molecules, T cell receptor signaling pathway, Intestinal immune network for IgA production, Malaria, Toxoplasmosis, Asthma, Autoimmune thyroid disease, Systemic lupus erythematosus, Allograft rejection, Primary immunodeficiency, Viral myocarditis, Lipid and atherosclerosis | Toralizumab 
                
                    Toralizumab
                
             💬
 | 
                
                    Toralizumab
                
             | [1]  63 63 💬
 |